Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART84 in R/R AML and T-ALL
NCT07471789Phase 2Recruiting
- Sponsor
- Gyala Therapeutics
- Start
- Feb 2026
- Primary completion
- May 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-CD84 CAR-T cells in acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), sponsored by Gyala Therapeutics. Started Feb 2026; status: recruiting.
02
Drugs
anti-CD84 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)T-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT07471789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07471789.